Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | PKM | P14618 | 1/20 | 0.54 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | GCGR | P47871 | 4/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CCNC | P24863 | 1/20 | 0.39 |
| ▸ | CDK8 | P49336 | 1/20 | 0.39 |
| ▸ | ABCC9 | O60706 | 1/20 | 0.39 |
| ▸ | ABCC8 | Q09428 | 1/20 | 0.39 |
| ▸ | KCNJ11 | Q14654 | 1/20 | 0.39 |
| ▸ | KCNJ8 | Q15842 | 1/20 | 0.39 |
| ▸ | RXRA | P19793 | 1/20 | 0.39 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5440013 | 0.79 | FFAR4 (0.66) | FFAR4FFAR1PTGDR2RXRARXRB | |
| SCHEMBL5428360 | 0.77 | PTGDR2 (0.45) | PKMFFAR4FFAR1PPARGPPARD | |
| SCHEMBL14544600 | 0.75 | FFAR1 (0.46) | PKMFFAR4FFAR1PPARGPPARD | |
| SCHEMBL21028305 | 0.73 | KDM4E (1.00) | KDM4EPKMNAMPTCNR1ABCC9 | |
| SCHEMBL14544598 | 0.68 | PTGDR2 (0.47) | FFAR4FFAR1GCGRPTGDR2 | |
| SCHEMBL3746360 | 0.68 | FFAR4 (0.66) | FFAR4FFAR1PTGDR2RXRARXRB | |
| SCHEMBL6777214 | 0.67 | KDM4E (0.49) | KDM4EPKMNAMPTPTGDR2ABCC9 | |
| SCHEMBL1573626 | 0.67 | KDM4E (0.72) | KDM4EPKMNAMPTABCC9ABCC8 | |
| SCHEMBL5417746 | 0.67 | PTGDR2 (0.62) | GCGRPTGDR2 | |
| SCHEMBL1995851 | 0.67 | PTGDR2 (0.76) | PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | claimed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | claimed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | claimed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | ASTRAZENECA AB (SE) | 2007-10-25 | — | — | US | disclosed |
| EP-1799658-A2 | MODULATORS OF CRTH2 REZEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | AstraZeneca AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006037982-A2 | MODULATORS OF CRTH2 RECEPTOR ACTIVITY FOR THE TREATMENT OF PROSTAGLANDIN D2 MEDIATED DISEASES | ASTRAZENECA AB (SE) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249686-A1 | Modulators of Crth-2 Receptor Activity for the Treatment of Prostaglandin D2 Mediated Diseases | PTGDR2, PTGDR, PTGER2 | KDM4E 4635/4885PKM 2382/4885FFAR4 286/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.